J Yang, J Ju, L Guo, B Ji, S Shi, Z Yang, S Gao… - Computational and …, 2022 - Elsevier
HER2-positive breast cancer is a highly heterogeneous tumor, and about 30% of patients
still suffer from recurrence and metastasis after trastuzumab targeted therapy. Predicting …